Ones To Watch News
Refine search
Biotechnology
California-based Braveheart Bio, a biotech developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced that Marc Evanchik has been promoted to chief scientific officer (CSO). 5 February 2026
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biotechnology
Pennsylvania, USA-based Third Arc Bio, a biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, has announced the closing of a $52 million series A extension. 4 February 2026
Biotechnology
UK biotech Levicept, which is focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announced the appointment of James Sandy as chief development officer (CDO). 4 February 2026
Biotechnology
Cambridge, UK-based biotech Bicycle Therapeutics, which is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced leadership transitions for its next phase of innovation. 3 February 2026
Biotechnology
Privately-held RNAi therapeutics specialist SanegeneBio has announced a global licensing agreement with the Roche subsidiary Genentech. 3 February 2026
Biotechnology
Norwegian cell therapy developer Zelluna has promoted Emilie Gauthy to chief technology officer, effective immediately. Ms Gauthy joined the company in 2022 and has led manufacturing and chemistry, manufacturing and controls work as Zelluna prepares to enter the clinic. 3 February 2026
Biotechnology
US biotech Wave Life Sciences has regained full rights to WVE-006 from British pharma GSK, bringing the RNA-editing therapy for alpha-1 antitrypsin deficiency back in-house as it prepares for higher-dose clinical data and steps up regulatory engagement. 3 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Pharmaceutical
Australian radiopharmaceutical company AdvanCell has entered into a collaboration and exclusive licensing deal with Canadian biotech 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic. 2 February 2026
Biotechnology
To date, 2025 has been the most active year for LifeArc Ventures. 2 February 2026
Biotechnology
French immuno-oncology company Kahimmune Therapeutics has announced the signing of an exclusive licensing agreement with cancer research hospital Gustave Roussy and technology transfer specialist SATT Paris-Saclay. 2 February 2026
Biotechnology
Australian oncology-focused biotech Kazia Therapeutics has reported pre-clinical and translational data supporting NDL2, a protein degrader designed to eliminate nuclear PD-L1, an intracellular driver of immunotherapy resistance and metastasis not addressed by approved checkpoint antibodies. 2 February 2026
Biotechnology
US genomics specialist Illumina has completed its acquisition of proteomics company SomaLogic, adding large-scale protein analysis to its multiomics portfolio and strengthening its push beyond sequencing into faster drug discovery and biomedical research. 2 February 2026
Pharmaceutical
US AI-driven biotech Insilico Medicine has struck a strategic drug discovery partnership with Chinese pharma group Qilu Pharmaceutical, aiming to develop small-molecule therapies for cardiometabolic diseases using artificial intelligence. 2 February 2026
Biotechnology
Resolve M Therapeutics has exited stealth, pitching a discovery platform designed to engage “pro-resolution” immune responses that could help restore immune balance in chronic inflammatory and autoimmune disorders, without broad immunosuppression. 2 February 2026
Biotechnology
Swiss biotech TECregen today announced the appointment of Dr Klaas Zuideveld, as chief executive (CEO). Dr Zuideveld will lead TECregen’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience. 2 February 2026
Pharmaceutical
US ophthalmology company SpyGlass Pharma has set out the terms of an initial public offering (IPO) in which the firms hopes to raise in excess of $150 million. 30 January 2026
Pharmaceutical
Privately-held Swedish neuropathic pain specialist PharmNovo has announced changes to its board of directors, welcoming two new members as the company prepares for its next phase of clinical development. 30 January 2026
Pharmaceutical
The chronic hepatitis D market is expected to grow steadily through 2034, supported by a small but advancing pipeline targeting a long-standing unmet need, according to research from DelveInsight. 30 January 2026
Biotechnology
Belgium’s largest pharma company UCB announced that it has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. 18 April 2026
Biotechnology
For most of oncology’s history, the fight against cancer has begun once the disease is diagnosed. UK-based Athernal Bio is building its platform around an earlier and potentially more powerful point of intervention: addressing biological changes in the body that accumulate silently before cancer develops. 17 April 2026
Pharmaceutical
Recently-launched US obesity company Kailera Therapeutics has announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. 17 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
California-based liver and viral disease specialist Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection, the company announced yesterday. 17 April 2026
Biotechnology
Genetic medicines company MeiraGTx Holdings has reacquired global rights to its Phase III gene therapy candidate for X-linked retinitis pigmentosa (XLRP), botaretigene sparoparvovec (bota-vec), from Johnson & Johnson, and priced a $100 million public offering of ordinary shares to support advancement of its late-stage pipeline. 16 April 2026
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze